• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Clearmind Medicine Inc. - Common Shares (NQ:CMND)

    1.160 -0.540 (-31.76%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 15,512,723
    Open 1.495
    Bid (Size) 1.160 (600)
    Ask (Size) 1.200 (300)
    Prev. Close 1.700
    Today's Range 1.160 - 1.555
    52wk Range 1.160 - 524.00
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Which stocks are experiencing notable movement on Friday? ↗
    Via Chartmill
    News headline image
    Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
    From Clearmind Medicine Inc.
    Via GlobeNewswire

    Performance

    YTD
    -94.2%
    -94.2%
    1 Month
    -33.7%
    -33.7%
    3 Month
    -69.4%
    -69.4%
    6 Month
    -88.6%
    -88.6%
    1 Year
    -99.7%
    -99.7%

    More News

    Read More
    News headline image
    Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    What's going on in today's pre-market session ↗
    Via Chartmill
    News headline image
    Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Monday's pre-market session: top gainers and losers ↗
    Via Chartmill
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
    From Clearmind Medicine Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Clearmind Medicine Inc. - Common Shares publicly traded?
    Yes, Clearmind Medicine Inc. - Common Shares is publicly traded.
    What exchange does Clearmind Medicine Inc. - Common Shares trade on?
    Clearmind Medicine Inc. - Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Clearmind Medicine Inc. - Common Shares?
    The ticker symbol for Clearmind Medicine Inc. - Common Shares is CMND on the Nasdaq Stock Market
    What is the current price of Clearmind Medicine Inc. - Common Shares?
    The current price of Clearmind Medicine Inc. - Common Shares is 1.160
    When was Clearmind Medicine Inc. - Common Shares last traded?
    The last trade of Clearmind Medicine Inc. - Common Shares was at 09/04/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.